Magle Chemoswed
brand development
The challenge
Two Companies
Magle Life Science the Swedish MedTech company creating innovative starch-based pharmaceutical products, acquired Chemoswed, a contract development and manufacturing organization (CDMO).
The two companies had very different ambitions, cultures, and strategies. This posed a significant challenge as the owners sought to increase vertical integration from the merger to capitalize on synergies.
The Solution
a new entity
A strategy was adopted to fully merge the two companies and their brands in order to achieve the objectives. The new entity, Magle Chemoswed, needed to communicate its complex offering in a succinct and effective way to the pharmaceutical market, as well as to investors and financial institutions.
The Solution
Brand Manual
A new visual identity was built from scratch in a full brand manual with distinct messaging and a clear tone of voice. Every customer-facing employee was provided communications training and was supported with all the required material, templates, and content. A new website with a focus on simplicity was designed and launched.
the solution
Investor Relations
Three years after the merger, the new entity went public. The IPO required specific communication material, including the creation of an appealing prospectus and investor material, as well as the set-up of an IR communications strategy and processes after the listing.
The solution
Value Creation
the impact
a guiding light
Justin Pierce, Chief Executive OfficerFrank Valiant proved to be the guiding light in a sea of uncertainty, seamlessly blending our two entities into a cohesive and impactful brand
500%
In the first three years after the merge, the company’s revenue increased by 50% and profitability doubled.
170%
The company was listed on Nasdaq First North and the share price rose 17% on the first day of trading.
2000m
By the end of the first year on the market, Magle Chemoswed’s share price had increased by 147%.